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Inflammation in the face of harming stimuli protects the
organism; as a result, it is an essential route for survival, in
which both innate and adaptive immunity are involved. This
process must be tightly controlled and terminated in order to
warrant the reestablishment of body homeostasis. Therefore,
activation of resident inflammatory cells and the recruitment
and modulation of migrating inflammatory cells must be
ceased. When failure in neutralizing acute inflammation
occurs, there is augmented risk of development of chronic
inflammation, leading to several metabolic consequences. In
the present special issue, original research studies as well
as review articles address the inflammatory process as a
key contributor to disease onset and progression. In addi-
tion, pharmacological and nonpharmacological therapies are
examined and the molecular and physiological mechanisms
of the treatments are discussed.
Among the 24 accepted papers, 7 approach nutritional
therapy and inflammation (J.-Y. Jhun et al.; E. A. Lima et al.;
H. B. F. Silva et al.; G. I. G. Souza et al.; B. M. Mohammed
et al.; C. A. Morais et al.; S. Arora et al.). The selected
papers discuss the effects of Macadamia oil supplementation
attenuation of adipocyte hypertrophy and of the inflam-
matory response of adipose tissue macrophages. The pro-
tection induced by supplementation of chitosan coacervate
whey protein against metabolic changes and obesity-related
inflammation is investigated. Other papers examine Jussara
supplementation-associated reversal of the adverse effects
of perinatal intake of transfatty acids, the beneficial effect
of red genistein extract on autoimmune arthritis, and the
role of vitamin C in the resolution of inflammation. Finally,
the promotion, by nutritional intervention, of the recovery
of glucose homeostasis is discussed. In addition, results on
the effect of microencapsulated probiotics on alcoholic liver
disease are presented. Taken together, these papers show new
encouraging results of nutritional therapy in counteracting
the symptoms of obesity and insulin resistance.
The ability of exercise to modulate chronic inflammation
was the center of two papers (C. P. Papini et al. and B. Koc
et al.,). These studies report that a community-based exercise
program results in decrease or maintenance of inflammatory
biomarkers after 1 year and thus presents strong potential in
public health approaches for chronic disease prevention.
Inflammation and its mechanisms are discussed in the
development and progression of many diseases, such as in
ectopic fat deposition (L. Liu et al.), acute and chronic kidney
disease (P. Ranganathan et al.), and polymicrobial sepsis (G.
Pizzino et al.). The role of interleukin- (IL-) 18 in the regula-
tion of toll-like receptors and mannose receptor expression
(L. A. Dias-Melicio et al.) is examined. Inflammation in
the metabolic syndrome (E. Hopps et al.) and the effect of
metformin on autoimmune arthritis (H.-J. Son et al.) are
debated. Gut microbiota participation in inflammation is
addressed (Mingming Sun et al.; Yu Lijuan et al.), and its reg-
ulation by short-chain fatty acids in diabetes (A. Puddu et al.)
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contemplated. The contribution of circulating LL-37 and
inflammatory cytokines in the setting of plaque and guttate
psoriasis (Y. J. Hwang et al.) is commented on. Other papers
consider ionotropic and metabotropic proton-sensing recep-
tors in allergic asthma (H. Aoki et al.) and autologous bone
marrow stem cell transplantation inmyocardial infarction (E.
B. Furenes et al.). Flavocoxid and infliximab are examined in
the context of classical and nutraceutical therapies (A. Bitto
et al.; L. Yu et al.). The role of IL-38 and related cytokines
in inflammation (X. Yuan et al.) is discussed, in addition
to gingival inflammation and pregnancy (M. Wu et al.) and
the contribution of the immune system in triplet repeat
expansion diseases (M. Olejniczak et al.).
Collectively, this issue provides insight on the role of acute
and chronic inflammation in different diseases and discusses
mechanisms and new treatment strategies.
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